Researchers develop promising recombinant influenza vaccine using nanoliposome technology
Recombinant protein vaccines, such as the Novavax vaccine used to fight COVID-19, offer several advantages over conventional vaccines. They are easy to precisely manufacture. They are safe and potentially more effective. And they may require smaller doses. Because of these characteristics, there is great interest in the development of recombinant influenza vaccines. To date, however, …